RxDoctor Payments Data

Guillermo Escobar, MD

Vascular Surgery · Little Rock, ARNPI 1427104025

Payments from drug & device makers

What this record shows

10 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 43.5% of the total. Reporting peaked in 2019 at $2,196 and has fallen 82.0% since, to $395 in 2025.

$3,739in general payments, 2019–2025

Across 32 payments — averaging $116.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$2K
  • Silk Road Medical, Inc.$856
  • Bolton Medical Inc$402
  • Penumbra, Inc.$325
  • Cook Medical LLC$294
  • Shockwave Medical, Inc$100
  • plus $135 from 4 others
$42,678in research payments, 2019–2025

Across 5 payments — averaging $8535.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$27K
  • Medtronic$16K

What the payments were for

  • Travel & lodging$1,65444%
  • Food & beverage$2,08556%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular surgery providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$96,906
Medicare patients
364
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban18$22,591
EliquisApixaban25$20,616
BrilintaTicagrelor13$8,305
Cilostazol69$1,471
ClopidogrelClopidogrel Bisulfate86$650
Nifedipine ErNifedipine12$536
Isosorbide Mononitrate ErIsosorbide Mononitrate12$383
Carvedilol20$358
Gabapentin16$296
Clonidine Hcl13$256
Atorvastatin Calcium27$211
Rosuvastatin Calcium14$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$22$22,59118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular surgery providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other vascular surgery in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →